An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.

National University Hospital, Singapore60 enrolled

Overview

The aim of this study is to determine the outcomes when using ertapenem for complicated urinary tract infections in the OPAt setting. The study hypothesis: Ertapenem is an efficacious and safe therapeutic option for complicated urinary tract infections in the OPAt setting.

Enterobactericae spp. is a common cause of urinary tract infections. The prevalence of quinolone-resistance in Enterobactericae is rising and often co-exists with expression of extended-spectrum beta-lactamases (ESBL, limiting viable outpatient therapeutics options. In Singapore, there is an increasing trend of treating patients who respond favourably to initial antimicrobial therapy in the outpatient setting (Fisher, et.al, 2006). Ertapenem is one of several agents with excellent antimicrobial activity against Enterobactericae (including ESBL producers). In view of its safety profile and its viability in elastromeric pump, it has great potential to be used in OPAT patients. There is no study analyzing outcomes in a large cohort of patients with complicated urinary tract infections treated with ertapenem.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Urinary Tract Infections

Interventions

ErtapenemDRUG

Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.

Eligibility

Sex: ALLMin age: 21 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients between 21 years old to 70 years old. * Diagnosed with complicated urinary tract infection due to pathogen susceptible to ertapenem based on microbiology report, and the use of ertapenem is deemed clinically appropriate by the Infectious Disease physician in charge. Exclusion Criteria: * Hypersensitivity reactions to Ertapenem. * Participation in another interventional clinical investigation within 30days * Unable to obtain informed consent.

Locations (1)

National University Hospital

Singapore, Singapore, Singapore

RECRUITING

Outcomes

Primary Outcomes

Clinical Outcome

Measured by: 1. Clinical features within 14 days of treatmnet:(improving/resolving/deteriorating) during therapy in OPAT eg dysuria,suprapubic pain, frequency, fever, urinalysis. 2. Clinical features of recurrences with 1 month after therapy completion 3. Presence of hospitalization and/or 4. Mortality

Time frame: within 14 days of treatment and within 1 months after the treatment completion.

Secondary Outcomes

Microbiology outcome

Measured by: urine culture results at the end of treatment and 30 days subsequent

Time frame: 30 days after completion of treatment

Central Contacts

Dale A Fisher

CONTACT

(65) 6772 43 73 dale_andrew_fisher@nuhs.edu.sg

Zuraidah Bt Sulaiman

CONTACT

(65) 6772 2083 Zuraidah_SULAIMAN@nuhs.edu.sg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.